Loading clinical trials...

Is Hemodialysis Associated With Cardiac Markers Change? | Clinical Trials | Clareo Health

COMPLETEDNA

Is Hemodialysis Associated With Cardiac Markers Change?

Effects of Hemodialysis With Cooled Dialysate on High Sensitive Cardiac Troponin I (TnI) and Brain Natriuretic Peptide (NT proBNP)

NCT04929366•Ziv Hospital

View on ClinicalTrials.gov

Summary

Hemodialysis (HD) triggers recurrent and cumulative ischemic insults to the brain and the heart. Cooled dialysate may have a protective effect on major organs and improve hemodynamic tolerability of dialysis. The aim of the study was to compare HD with cooled dialysate with routine dialysis in terms of hemodynamic stability and levels of high sensitivity Troponin I (hs-TnI) and N-terminal pro b-type natriuretic peptide (NTproBNP) post dialysis

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with renal insufficiency treated with dialysis for a period of at least three months.

Exclusion Criteria

•Patients who experienced myocardial infarction during the three months prior to the start of the study
•Patients who underwent vascular surgery during the last month
•Patients who experienced chest pain at rest during the last week before the start of the trial - Patients who had to discontinue dialysis prematurely due to hemodynamic instability.

Locations (1)

Nephrology Department, Ziv Medical Center

Safed, Israel

Key Dates

Start Date

December 18, 2017

Primary Completion Date

November 16, 2020

Completion Date

November 16, 2020

Last Updated

June 18, 2021

Enrollment

ACTUAL participants

Conditions

Renal Insufficiency, Chronic

Interventions

Hypothermic dialysis followed with routine dialysis

PROCEDURE

Routine dialysis followed with hypothermic dialysis

PROCEDURE

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

NCT06314503

Renal Insufficiency, ChronicKidney Failure, Chronic+1 more

View study

RECRUITINGPHASE1/PHASE2

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

NCT06863194

Kidney Disease, ChronicRenal Insufficiency, Chronic+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Is Hemodialysis Associated With Cardiac Markers Change?

Inclusion Criteria

Exclusion Criteria

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

Effects of Exogenous Ketosis on Proteinuria and Renal Function

Penn Produce Prescription and Chronic Kidney Disease Study

Acute Kidney Injury Genomics and Biomarkers in TAVR Study

Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP